8-K Announcements
6Material company update
May 18, 2026·SEC
Material company update
Mar 20, 2026·SEC
Material company update
Mar 13, 2026·SEC
60 Degrees Pharmaceuticals, Inc.(SXTP)Earnings, Financials & Key Ratios
SXTP•NASDAQ
$1.75
Price updated Jul 7, 2026
About60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.Show more
- Revenue$1M+65.5%
- EBITDA-$8M+20.5%
- Net Income-$7M+7.3%
- EPS (Diluted)-11.73+84.2%
- Gross Margin22.26%-39.3%
- EBITDA Margin-763.39%+51.9%
- Operating Margin-771.64%+51.7%
- Net Margin-732.82%+44.0%
- ROE-200.92%-10.7%
SXTP Price & Volume
60 Degrees Pharmaceuticals, Inc. (SXTP) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operating Losses Threaten Capital Base Sustainability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent Liquidity Exhaustion
Key Thesis Takeaways
- 60 Degrees Pharmaceuticals faces a challenging outlook as its commercialization of Arakoda fails to generate sufficient revenue to offset high operating expenses, which reached $1.9 million in 2026Q1.
- The company's reliance on external capital is underscored by an accumulated deficit of $50.0 million, raising significant concerns regarding long-term solvency.
- Investors should monitor the company's inability to achieve operating leverage, as evidenced by consistent quarterly operating losses that frequently exceed $2 million.
Verdict Logic
the company's inability to achieve self-sustaining cash flow is evidenced by a 2026Q1 OCF/NI ratio of 1.31, suggesting that current operations are fundamentally dilutive to shareholder value.
SXTP Growth Metrics
60 Degrees Pharmaceuticals, Inc. (SXTP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-14.35%
3 Years65.15%
TTM46.52%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM26.09%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM77.04%
Return on Capital
10 Years-134.89%
5 Years-159.7%
3 Years-174.11%
Last Year-203.49%
SXTP Recent Earnings
60 Degrees Pharmaceuticals, Inc. (SXTP) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (18%)●Beat Revenue 3/12 qtrs (27%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$1.28-68.4%
$0.76
Rev
$162,092-62.7%
$435,000
Q2 2026
Mar 26, 2026Metric
Actual
Est
EPS
$1.91+16.2%
$2.28
Rev
$300,000-6.3%
$320,000
Q4 2025
Nov 13, 2025Metric
Actual
Est
EPS
$2.64-43.5%
$1.84
Rev
$437,602+118.8%
$200,000
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$1.25-0.8%
$1.24
Rev
$100,932-32.7%
$150,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $1.28vs $0.76-68.4% | $162,092vs $435,000-62.7% |
| Q2 2026 | Mar 26, 2026 | $1.91vs $2.28+16.2% | $300,000vs $320,000-6.3% |
| Q4 2025 | Nov 13, 2025 | $2.64vs $1.84-43.5% | $437,602vs $200,000+118.8% |
| Q3 2025 | Aug 13, 2025 | $1.25vs $1.24-0.8% | $100,932vs $150,000-32.7% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for 60 Degrees Pharmaceuticals, Inc. (SXTP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.75 | $1.41M | -0.15 | 65.49% | -732.82% | -200.92% | — | |
| $7.41 | $92.58M | -29.64 | 14.52% | -9.05% | -70.95% | — | |
| $0.62 | $3.45M | -0.31 | — | — | -204.27% | — | |
| $1.49 | $955.87M | -11.46 | 138.83% | -35.48% | -28.9% | — | |
| $5.67 | $1.97B | -9.45 | 698.96% | -102.06% | -44.1% | — | |
| $81.57 | $9.68B | 31.86 | 37.55% | 23.13% | 126.27% | — |
Compare SXTP vs Peers
60 Degrees Pharmaceuticals, Inc. (SXTP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SXTP SEC Filings & Documents
60 Degrees Pharmaceuticals, Inc. (SXTP) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when SXTP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SXTP Frequently Asked Questions
60 Degrees Pharmaceuticals, Inc. (SXTP) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is 60 Degrees Pharmaceuticals, Inc.'s revenue?
60 Degrees Pharmaceuticals, Inc. (SXTP) reported $1.0M in revenue for fiscal year 2025. This represents a 54% decrease from $2.2M in 2020.
How fast is 60 Degrees Pharmaceuticals, Inc. growing?
60 Degrees Pharmaceuticals, Inc. (SXTP) grew revenue by 65.5% over the past year. This is strong growth.
Is SXTP profitable?
60 Degrees Pharmaceuticals, Inc. (SXTP) reported a net loss of $7.6M for fiscal year 2025.
Dividend & Returns
What is SXTP's return on equity?
60 Degrees Pharmaceuticals, Inc. (SXTP) has a return on equity (ROE) of -200.9%. Negative ROE indicates the company is unprofitable.
What is 60 Degrees Pharmaceuticals, Inc.'s free cash flow?
60 Degrees Pharmaceuticals, Inc. (SXTP) had negative free cash flow of $8.2M in fiscal year 2025, likely due to heavy capital investments.